{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:05:08Z","timestamp":1789639508589,"version":"4.0.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03793-z","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:47:19Z","timestamp":1789638439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Uncontrolled Motor Fluctuations in Parkinson\u2019s Disease: Real-World Insights from the PROSPECT Observational Study"],"prefix":"10.1007","author":[{"given":"Alberto J.","family":"Espay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Defebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"de Fabregues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ledingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Oeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory-Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna R.","family":"Sarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaram","family":"Safarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Onuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Sanchez","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"3793_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2010;24:119\u201329. https:\/\/doi.org\/10.2165\/11310940-000000000-00000.","journal-title":"CNS Drugs"},{"key":"3793_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3389\/fneur.2019.00799","volume":"10","author":"I Straka","year":"2019","unstructured":"Straka I, Min\u00e1r M, \u0160korv\u00e1nek M, Grofik M, Danterov\u00e1 K, Benetin J, et al. Adherence to pharmacotherapy in patients with Parkinson\u2019s disease taking three and more daily doses of medication. Front Neurol. 2019;10:799. https:\/\/doi.org\/10.3389\/fneur.2019.00799.","journal-title":"Front Neurol"},{"key":"3793_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Chaudhuri KR, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21:1133\u201344. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.020.","journal-title":"Parkinsonism Relat Disord"},{"key":"3793_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, Isaacson SH, Merola A, Wang L, et al. Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2022;36:1269\u201383. https:\/\/doi.org\/10.1007\/s40263-022-00963-9.","journal-title":"CNS Drugs"},{"key":"3793_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19:50. https:\/\/doi.org\/10.1186\/s12883-019-1276-8.","journal-title":"BMC Neurol"},{"key":"3793_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20:224\u201330. https:\/\/doi.org\/10.1002\/mds.20279.","journal-title":"Mov Disord"},{"key":"3793_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jns.2013.07.005","volume":"332","author":"D Santos-Garc\u00eda","year":"2013","unstructured":"Santos-Garc\u00eda D, de la Fuente-Fern\u00e1ndez R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson\u2019s disease. J Neurol Sci. 2013;332:136\u201340. https:\/\/doi.org\/10.1016\/j.jns.2013.07.005.","journal-title":"J Neurol Sci"},{"key":"3793_CR8","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00415-022-11546-5","volume":"270","author":"P Martinez-Martin","year":"2023","unstructured":"Martinez-Martin P, Skorvanek M, Henriksen T, Lindvall S, Domingos J, Alobaidi A, et al. Impact of advanced Parkinson\u2019s disease on caregivers: an international real-world study. J Neurol. 2023;270:2162\u201373. https:\/\/doi.org\/10.1007\/s00415-022-11546-5.","journal-title":"J Neurol"},{"key":"3793_CR9","doi-asserted-by":"publisher","unstructured":"Pharmacoepidemiology International Society of Guidelines for good pharmacoepidemiology practice (GPP) PPC, Pharmacoepidemiol. Drug Saf. 25 (2016) 2\u201310. https:\/\/doi.org\/10.1002\/pds.3891.","DOI":"10.1002\/pds.3891"},{"key":"3793_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51:745. https:\/\/doi.org\/10.1136\/jnnp.51.6.745.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3793_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C. Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and Safinamide. Mov Disord Clin Pract. 2020;7:343\u20135. https:\/\/doi.org\/10.1002\/mdc3.12921.","journal-title":"Mov Disord Clin Pract"},{"key":"3793_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.23638","volume":"26","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Auinger P, P.S. Group. Determination of minimal clinically important change in early and advanced Parkinson\u2019s disease. Mov Disord. 2011;26:813\u20138. https:\/\/doi.org\/10.1002\/mds.23638.","journal-title":"Mov Disord"},{"key":"3793_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society\u2013sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32:789\u201393. https:\/\/doi.org\/10.1002\/mds.26960.","journal-title":"Mov Disord"},{"key":"3793_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant? Neuroepidemiology. 2017;48:1\u20138. https:\/\/doi.org\/10.1159\/000455863.","journal-title":"Neuroepidemiology"},{"key":"3793_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1474-4422(13)70293-x","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141\u20139. https:\/\/doi.org\/10.1016\/s1474-4422(13)70293-x.","journal-title":"Lancet Neurol"},{"key":"3793_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749\u201359. https:\/\/doi.org\/10.1016\/s1474-4422(18)30239-4.","journal-title":"Lancet Neurol"},{"key":"3793_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced parkinson disease: a randomized controlled trial. JAMA. 2009;301:63\u201373. https:\/\/doi.org\/10.1001\/jama.2008.929.","journal-title":"JAMA"},{"key":"3793_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02074-2","volume":"21","author":"A Thach","year":"2021","unstructured":"Thach A, Jones E, Pappert E, Pike J, Wright J, Gillespie A. Real-world assessment of the impact of \u201cOFF\u201d episodes on health-related quality of life among patients with Parkinson\u2019s disease in the United States. BMC Neurol. 2021;21:46. https:\/\/doi.org\/10.1186\/s12883-021-02074-2.","journal-title":"BMC Neurol"},{"key":"3793_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/ene.12950","volume":"23","author":"KM Prakash","year":"2016","unstructured":"Prakash KM, Nadkarni NV, Lye W-K, Yong M-H, Tan E-K. The impact of non\u2010motor symptoms on the quality of life of Parkinson\u2019s disease patients: a longitudinal study. Eur J Neurol. 2016;23:854\u201360. https:\/\/doi.org\/10.1111\/ene.12950.","journal-title":"Eur J Neurol"},{"key":"3793_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez\u2010Martin","year":"2011","unstructured":"Martinez\u2010Martin P, Rodriguez\u2010Blazquez C, Kurtis MM, Chaudhuri KR, B. of the N.V. Group. The impact of non\u2010motor symptoms on health\u2010related quality of life of patients with Parkinson\u2019s disease. Mov Disord. 2011;26:399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462.","journal-title":"Mov Disord"},{"key":"3793_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.parkreldis.2016.12.027","volume":"36","author":"J Yang","year":"2017","unstructured":"Yang J, Hanna-Pladdy B, Gruber-Baldini AL, Barr E, von Coelln R, Armstrong MJ, et al. Response shift \u2013 the experience of disease progression in Parkinson disease. Parkinsonism Relat Disord. 2017;36:52\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.12.027.","journal-title":"Parkinsonism Relat Disord"},{"key":"3793_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mds.21429","volume":"22","author":"A Schrag","year":"2007","unstructured":"Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson\u2019s disease. a prospective study. Mov Disord. 2007;22:938\u201345. https:\/\/doi.org\/10.1002\/mds.21429.","journal-title":"Mov Disord"},{"key":"3793_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34:2063\u201373. https:\/\/doi.org\/10.1080\/03007995.2018.1502165.","journal-title":"Curr Med Res Opin"},{"key":"3793_CR24","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, \u015ami\u0142owska K, Berg D, Corvol J, et al. European Academy of Neurology\/Movement Disorder Society \u2010 European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Eur J Neurol. 2022;29:2580\u201395. https:\/\/doi.org\/10.1111\/ene.15386.","journal-title":"Eur J Neurol"},{"key":"3793_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-021-00313-9","volume":"11","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, et al. Psychometric properties of clinical indicators for identification and management of advanced Parkinson\u2019s disease: real-world evidence from G7 countries. Neurol Ther. 2022;11:303\u201318. https:\/\/doi.org\/10.1007\/s40120-021-00313-9.","journal-title":"Neurol Ther"},{"key":"3793_CR26","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret M, Weiss D, Stocchi F, V\u00e9rin M, Jost WH. Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm. 2023;130:1411\u201332. https:\/\/doi.org\/10.1007\/s00702-023-02668-9.","journal-title":"J Neural Transm"},{"key":"3793_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ane.13648","volume":"146","author":"A Fasano","year":"2022","unstructured":"Fasano A, Fung VSC, Seppi K, Pirtosek Z, Tak\u00e1ts A, Alobaidi A, et al. Intercountry comparisons of advanced Parkinson\u2019s disease symptoms and management: analysis from the OBSERVE-PD observational study. Acta Neurol Scand. 2022;146:167\u201376. https:\/\/doi.org\/10.1111\/ane.13648.","journal-title":"Acta Neurol Scand"},{"key":"3793_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Park Relat Disord. 2021;92:59\u201366. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.10.009.","journal-title":"Park Relat Disord"},{"key":"3793_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/03007995.2022.2129800","volume":"39","author":"S Fujioka","year":"2023","unstructured":"Fujioka S, Mishima T, Yamazaki T, Bebrysz M, Nomoto M, Yamaguchi J, et al. Neurologists\u2019 preferences for device-aided therapy for advanced Parkinson\u2019s disease in Japan. Curr Med Res Opin. 2023;39:91\u2013104. https:\/\/doi.org\/10.1080\/03007995.2022.2129800.","journal-title":"Curr Med Res Opin"},{"key":"3793_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40120-024-00635-4","volume":"13","author":"K Poplawska-Domaszewicz","year":"2024","unstructured":"Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR. Subcutaneous levodopa: a new engine for the vintage molecule. Neurol Ther. 2024;13:1055\u201368. https:\/\/doi.org\/10.1007\/s40120-024-00635-4.","journal-title":"Neurol Ther"},{"key":"3793_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00896","volume":"10","author":"FAP Nijhuis","year":"2019","unstructured":"Nijhuis FAP, van den Heuvel L, Bloem BR, Post B, Meinders MJ. The patient\u2019s perspective on shared decision-making in advanced Parkinson\u2019s disease: a cross-sectional survey study. Front Neurol. 2019;10:896. https:\/\/doi.org\/10.3389\/fneur.2019.00896.","journal-title":"Front Neurol"},{"key":"3793_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105514","volume":"116","author":"HH Fernandez","year":"2023","unstructured":"Fernandez HH, Odin P, Standaert DG, Henriksen T, Jimenez-shahed J, Metz S, et al. Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson\u2019s disease continuum: revelations from the MANAGE-PD validation cohort. Park Relat Disord. 2023;116:105514. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105514.","journal-title":"Park Relat Disord"},{"key":"3793_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1877718x261425106","volume":"16","author":"ME Fullard","year":"2026","unstructured":"Fullard ME, Shelton E, Dafoe A, Kern DS, Morris MA, Matlock DD. Development and acceptability of a deep brain stimulation surgery decision aid for Parkinson\u2019s disease. J Parkinsons Dis. 2026;16:589\u201398. https:\/\/doi.org\/10.1177\/1877718x261425106.","journal-title":"J Parkinsons Dis"},{"key":"3793_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00415-025-12972-x","volume":"272","author":"FAP Nijhuis","year":"2025","unstructured":"Nijhuis FAP, Schippers B, Bloem BR, Post B, Meinders MJ. A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson\u2019s disease: results of a mixed methods feasibility study. J Neurol. 2025;272:269. https:\/\/doi.org\/10.1007\/s00415-025-12972-x.","journal-title":"J Neurol"},{"key":"3793_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-026-00920-4","author":"P Arija","year":"2026","unstructured":"Arija P, Domingos J, Malaty IA, Pahwa R, Chaudhuri KR, Antonini A, et al. Exploring preferences and priorities in advanced Parkinson\u2019s Disease: a discrete choice experiment. Neurol Ther. 2026. https:\/\/doi.org\/10.1007\/s40120-026-00920-4.","journal-title":"Neurol Ther"},{"key":"3793_CR36","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/s1474-4422(16)00066-1","volume":"15","author":"F Benedetti","year":"2016","unstructured":"Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15:736\u201347. https:\/\/doi.org\/10.1016\/s1474-4422(16)00066-1.","journal-title":"Lancet Neurol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03793-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03793-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:47:20Z","timestamp":1789638440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03793-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":36,"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03793-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alberto J. Espay: has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant\/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acadia, Acorda, Abbvie, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Praxis Precision Medicines, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He is co-inventor of the patent \u201cCompositions and methods for treatment and\/or prophylaxis of proteinopathies\u201d with which he cofounded REGAIN Therapeutics to fund preclinical studies. He has no financial relationship with the company and relinquished the right to any personal income from future treatments. Dr. Espay owns no stock in any pharmaceutical company with which he has a scientific advisory relationship. He serves on the editorial boards of the\n                      Journal of Parkinson\u2019s Disease\n                      ,\n                      Journal of Alzheimer\u2019s Disease\n                      ,\n                      European Journal of Neurology\n                      ,\n                      Movement Disorders Clinical Practice\n                      , and\n                      JAMA Neurology\n                      . Luc Defebvre: has served as an advisory board member for AbbVie and Aguettant. He has received travel grants from AbbVie and Orkyn. He has served as a consultant for AbbVie and Orkyn. Oriol de Fabregues: has received honoraria from AbbVie, Alexion, Ferrer, and Italfarmaco. Drew Falconer: has received consultancy or speaker fees from AbbVie, Abbott, Acorda Therapeutics, Amneal, GE HealthCare, Kyowa Kirin, Neurocrine, and Sunovion; he receives compensation as a subject-matter expert from the Federal Trade Commission and the Justice Department. Kazuko Hasegawa: receives a salary from NHO Sagamihara Hospital and research grants from AbbVie, Otsuka, Boehringer-Ingelheim, Eisai, and Ministry of Health, Labour Welfare of Japan. David J. Houghton: has received consultancy or speaker fees from AbbVie and Teva. David Ledingham: has received research support from Dystonia Europe, Michael J. Fox Foundation, Medtronic and Roche, royalties from Oxford University Press, and has served as an advisor and speaker for Bial, Ipsen, and Merz. Alexander Lehn: has received educational grants from Abbott, Medtronic, and Ipsen. He has received honoraria for educational presentations from AbbVie and SEER medical. Tiago A. Mestre: has received research support from the Canadian Institutes of Health Research, the Ontario Research Fund, Michael J. Fox Foundation, Parkinson Canada, University of Ottawa\/Parkinson Research Consortium, Weston Brain Foundation; personal compensation as consultant for AbbVie, CHDI, Sunovion, Roche, Biogen, Takeda, personal compensation as honoraria and for speakers bureau for AbbVie. Tomoko Oeda: has served as an advisor or speaker for several organizations, including AbbVie, Takeda, Eisai, Ono Pharma, Kyowa Kirin, and FP Pharma. Furthermore, she has received funding from the Japan Blood Products Organization. Fabienne Ory-Magne: has served as an advisory board member for AbbVie, Aguettant, Actelion, Univar and Orkyn. She has received travel grants from AbbVie and Actelion. She reports grants from France-Parkinson Association, and Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. She has served as a consultant for AbbVie, AGUETTANT, LVL Medical, Medtronic, NHC France, and Orkyn. Justyna Sarna: has received consultancy fees from AbbVie. Delaram Safarpour: has received research support from Medtronic and Amneal for research. She has received honorarium for teaching from Boston Scientific and has served as an advisory board member for AbbVie, Medtronic, and Boston Scientific. She has received compensation for consulting from 2nd.MD. Sam Colman: employee of Fortrea who was contracted by AbbVie to undertake the study. Lars Bergmann, Pavnit Kukreja, Koray Onuk, Connie H. Yan: employees of AbbVie. Pilar Sanchez Alonso: has received honoraria for educational presentations and advisory services from AbbVie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Esteve, and Teva.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the guidelines for good pharmacoepidemiology practices in non-interventional studies and with all applicable local laws and regulations and the 1964 Declaration of Helsinki and its following amendments. Approval was obtained from the relevant independent ethics committees and\/or institutional review boards and conducted in accordance with local laws and regulations. A table listing the names of all participating ethics committees is provided in the supplementary materials. Written informed consent was obtained from the patient or authorized representative prior to study inclusion.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}